Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International Study to Predict Optimised Treatment Response to Short-Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.

Next Previous
Trial Profile

International Study to Predict Optimised Treatment Response to Short-Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 29 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Acronyms iSPOT-A

Most Recent Events

  • 23 Oct 2013 Planned end date changed from 1 Jul 2013 to 1 Jul 2016 as reported by ClinicalTrials.gov.
  • 05 Jan 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
  • 13 May 2011 Planned end date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top